iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.

Biotechnology

iECURE

iECURE's headquarters in Philadelphia, PA, United States

This department focuses on advancing market opportunities and overseeing the management of manufacturing science and technology for upstream and downstream processes.

Market Development

The Leadership Team at iECURE is responsible for shaping the strategic direction and operational execution of the company’s mission to develop innovative gene therapies for liver disorders. This multidisciplinary team, composed of executives with expertise in clinical trials, finance, regulatory affairs, and patient advocacy, ensures alignment between research initiatives and business objectives while fostering collaborations and guiding the clinical and technical strategies necessary for successful product development and commercialization. Together, they leverage their extensive experience to drive iECURE's goal of delivering transformative therapies to patients with significant unmet medical needs.

Leadership Team

The Regulatory and Quality Assurance Team at iECURE is responsible for ensuring that the company's gene editing therapies meet all regulatory requirements and quality standards throughout the development process. They collaborate with various stakeholders to navigate the regulatory landscape, facilitate compliance with clinical trial regulations, and implement robust quality assurance practices. Their expertise is critical in advancing the potential product candidates through regulatory submissions and ensuring the safety and efficacy of therapies designed to treat liver disorders.

Regulatory and Quality Assurance Team

This department oversees the organization's board activities and provides strategic guidance for decision-making.

Board Governance

The Clinical Operations Team at iECURE is responsible for overseeing the planning, execution, and management of clinical trials focused on gene editing therapies for liver disorders. This team ensures compliance with regulatory standards, coordinates trial activities, and collaborates closely with cross-functional teams to optimize study design and patient recruitment. Through their expertise, they aim to advance innovative treatments from the laboratory to clinical settings, ultimately working towards improved patient outcomes.

Clinical Operations Team

This department focuses on managing and supporting medical activities in the field to ensure effective communication and collaboration between the organization and healthcare professionals.

People (3)

Jobs (0)

Other teams

Leadership Team

Regulatory and Quality Assurance Team

Board Governance

Clinical Operations Team

Field Medical Affairs